Literature DB >> 10909286

[Diagnosis, treatment and prognosis in cases of renal clear cell carcinoma metastases into the thyroid gland].

M Barczyński1, J Jamski, S Cichoń, M Barczyński1, W Sułowicz.   

Abstract

The most common metastatic tumour of the thyroid gland which is clinically revealed is renal clear cell carcinoma (RCCC). Our clinical experience in cases of RCCC metastases into thyroid gland is reviewed in terms of the history of the disease, obligatory diagnostic procedures, surgical management and outcome prognosis. We believe that all the patients with even a remote RCCC history require systematic follow-up including thyroid gland as metachronic metastatic disease can occur many years after primary surgery. Clinical diagnosis and ultrasound of the thyroid gland is essential in selection for surgical treatment. Confirmation of malignancy in FNA (fine needle aspiration) in often difficult regarding concomitant multinodular goitre. Enlargement of a single thyroid nodule except L-thyroxin therapy for 3-6 months is a sufficient indication for surgical treatment, not depending on FNA result, particularly when a suspected nodule becomes bigger than 30 mm in diameter.

Entities:  

Mesh:

Year:  2000        PMID: 10909286

Source DB:  PubMed          Journal:  Przegl Lek        ISSN: 0033-2240


  3 in total

1.  Metastases to the thyroid gland: seventeen cases operated on in a single clinical center.

Authors:  Stanisław Cichoń; Ryszard Anielski; Aleksander Konturek; Marcin Barczyński; Wojciech Cichoń
Journal:  Langenbecks Arch Surg       Date:  2006-09-16       Impact factor: 3.445

Review 2.  Isolated thyroid metastasis revealed an unknown lung adenocarcinoma: a case report.

Authors:  J Khalil; F Elomrani; M Benoulaid; H Elkacemi; T Kebdani; H Errihani; N Benjaafar
Journal:  J Med Case Rep       Date:  2015-09-27

3.  Metastases to the thyroid gland: A report of 32 cases in PUMCH.

Authors:  Liyang Zhang; Yuewu Liu; Xiaoyi Li; Weisheng Gao; Chaoji Zheng
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.